News

The Chinese market is growing rapidly, and demand for Luminex’s multiplexing technologies among scientists in China is strong, said Patrick J. Balthrop, president and chief executive officer of

Pfizer has announced the launch of Toviaz (fesoterodine fumarate), an extended release tablets and YourWay plan, a customizable support plan for overactive bladder patients, which are now available

The AmerisourceBergen has purchased Innomar Strategies, a Canadian specialty pharmaceutical services company, for approximately C$15 million ($13.8 million) in cash, subject to a working capital adjustment. David Yost,

Concert Pharmaceuticals and GlaxoSmithKline have formed an alliance to develop and commercialize deuterium-containing medicines. The deal includes three of Concert’s research and development programs, CTP-518, a protease inhibitor

Cerus, and a subsidiary of Grifols have announced that the two companies have entered into an agreement to collaborate on the development of red blood cell treatment sets

NeurogesX has declared that the Office of Orphan Product Development (OOPD) of the FDA has granted orphan drug designation for Qutenza (formerly NGX-4010), a high concentration capsaicin dermal

Nanogen on May 14, 2009, has filed a voluntary petition under chapter 11 bankruptcy protection and had inked the agreement to sell substantially all of its assets to

Medivation has declared the new clinical results from a phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings,

Lamictal XR is approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalization. Lamictal XR reduced the frequency of